Summary
VITAL is a large-scale randomised controlled trial of marine omega-3 fatty acid supplementation (1 g/day) versus placebo in 25,871 US adults aged ≥50/≥55 years for primary cardiovascular and cancer prevention. Whilst supplementation did not reduce overall major cardiovascular disease events, it significantly reduced total myocardial infarction, fatal myocardial infarction, coronary revascularisation procedures, and heart failure hospitalisation, and was associated with reduced autoimmune disease risk. The intervention showed no effect on atrial fibrillation, cancer incidence, or all-cause mortality, with treatment effects modified by race, baseline fish intake, and cardiovascular risk profile.
Regional applicability
The study was conducted in the United States and may have limited direct applicability to UK populations, which typically have different dietary patterns, healthcare systems, and demographic profiles. However, the findings are relevant to UK evidence on omega-3 supplementation efficacy for cardiovascular disease prevention and could inform NHS guidance on fish oil supplementation, particularly regarding selective cardiac benefits in lower-risk general populations.
Key measures
Hazard ratios for major cardiovascular disease events, myocardial infarction (total and fatal), percutaneous coronary intervention, heart failure hospitalisation, atrial fibrillation, cancer incidence, autoimmune disease, all-cause mortality; effect modification by demographic, dietary and clinical factors
Outcomes reported
The study measured effects of 1 g/day marine omega-3 fatty acid supplementation on major cardiovascular disease events, myocardial infarction, heart failure, atrial fibrillation, cancer incidence, autoimmune disease, and all-cause mortality over a median 5.3-year follow-up period in 25,871 adults.
Topic tags
Dig deeper with Pulse AI.
Ask about this record, its theme or its relevance to UK farming and policy. Pulse AI uses selected catalogue evidence and cites the sources it draws on.